Product information:
| Product name |
Simvastatin tablets |
| Use |
Lipid-Lowering |
| Shelf Life |
24 Months |
| Storage |
Airtight and kept under 30 ºC. |
| Specifications |
5mg 10*10/box |
Indication:
Hyperlipidemia for patients with primary hypercholesterolemia, including heterozygous familial hypercholesterolemia, hyperlipidemia or mixed hyperlipidemia, when diet control and other non drug treatment are not ideal, combined with diet control, this product can be used to reduce elevated total cholesterol, low-density lipoprotein cholesterol, apolipoprotein B and triglycerides, and increase high-density lipoprotein Cholesterol, thereby reducing the ratio of LDL / HDL-C and TC / HDL-C. For homozygous familial hypercholesterolemia patients, combined with diet control and non diet therapy, can be used to reduce elevated total cholesterol, low-density lipoprotein cholesterol and apolipoprotein B.
Coronary heart disease for patients with coronary heart disease and hypercholesterolemia, this product is suitable for: reducing the risk of death, reducing the risk of coronary heart disease death and non fatal myocardial infarction, reducing the risk of stroke and transient cerebral ischemia, reducing the risk of cardiac vascular reconstruction surgery (coronary artery bypass grafting and percutaneous transluminal coronary angioplasty), and delaying the progression of coronary atherosclerosis The course includes reducing the formation of new lesions and total occlusion
Children with heterozygous familial hypercholesterolemia. For adolescent boys and girls aged 10-17 years with heterozygous familial hypercholesterolemia (at least one year after menarche), combined with diet control, this product can be used to reduce total cholesterol, low-density lipoprotein cholesterol, apolipoprotein B and triglycerides.
Taboo:
----Allergic to any ingredient of this product
----Patients with active liver disease or unexplained elevated serum transaminase
----Pregnant and lactating women (see precautions, medication for pregnant and lactating women)
---In combination with strong CYP3A4 inhibitors (e.g., itraconazole, ketoconazole, posaconazole, voriconazole, HIV protease inhibitors, boprivir, tirarevir, erythromycin, clarithromycin, talimycin, and nefazodone) (see notes, myopathy / rhabdomyolysis, and drug interactions).
---In combination with gemfibrozil, cyclosporin or danazol (see caution, myopathy / rhabdomyolysis, and drug interactions)
Pharmacology and Toxicology:
Simvastatin can reduce the concentration of normal and elevated low density lipoprotein cholesterol (LDL-C). LDL is formed by very low density lipoprotein (VLDL) and is mainly metabolized by high affinity LDL receptor. The mechanism of simvastatin reducing LDL-C mainly includes: reducing the concentration of VLDL cholesterol, inducing LDL receptor, leading to the decrease of LDL cholesterol and increasing the catabolism of LDL-C. During simvastatin treatment, the level of apolipoprotein B (apo B) also decreased significantly. Since each LDL particle contains one molecule of apo B, and apo B is rarely found in other lipoproteins, this suggests that simvastatin can not only make cholesterol lose from LDL, but also reduce the concentration of circulating LDL particles. In addition, simvastatin can increase the concentration of high density lipoprotein cholesterol (HDL-C) and reduce the plasma triglyceride (TG). These can lead to the decrease of total cholesterol / HDL-C and LDL-C / HDL-C.
Audited Supplier 
){kind=link}